Developing innovative drugs for the treatment of liver diseases

Learn more about Tiziana

Notice of Annual General Meeting

07 May 2019

Tiziana Life Sciences plc announces that its Annual General Meeting will be held at 10:00 a.m. on Friday 31 May 2019 at the offices of Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS.

Read more

PDMR dealings

02 May 2019

Tiziana announces that on 1 May 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought ordinary shares of nominal value 3p each in the capital of the Company, as set out below, following prior consultation with the Takeover Panel in relation to Note 11 to Rule 9.1 of the City Code on Takeovers and Mergers.

Read more

Update on IND Application for Oral Formulation of Foralumab for Treatment of NASH

01 May 2019

Tiziana announces an update regarding its Investigational New Drug application to the FDA to initiate a Phase 1 clinical trial of enteric-coated capsules of Foralumab in healthy volunteers.

Read more

Our Mission

Our mission is to bring breakthrough therapies to patients with the aim of reversing severe liver diseases, autoimmune and inflammatory diseases and optimizing health outcomes.

Learn more

Clinical Candidates

With several candidates in the clinic, our development portfolio is supported by extensive IP and a strong pipline of in-licenced clinical and pre-clinical assets.

Clinical development pipeline

Milciclib

Milciclib is the Company’s Phase 2 clinical candidate for the treatment of multiple cancer indications such as hepatocellular carcinoma, thymic cancer and thymoma.

Learn more about Milciclib

Foralumab

Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of NASH, Crohn’ s Disease and a neurodegenerative indication.

Learn more about Foralumab

Pre-Clinical Candidates

With several candidates being prepared for clinic, our development portfolio is supported by extensive IP and a strong pipline of in-licenced clinical and pre-clinical assets.

Anti IL-6r (TZLS-501)

We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6. This asset was in-licensed from Novimmune in January 2017.

Learn more about Anti IL-6r

StemPrintER™

StemPrintER is a multi-gene signature assay intended for use as a diagnostic screen in patients with estrogen-receptor positive ER+/HER2 negative breast cancers.

Learn more about StemPrintER™

Clinical Trials

Tiziana is currently conducting clinical development programs for Foralumab and Milciclib

Milciclib

We initiated a Phase 2a trial (CDKO-125a-010) of Milciclib safety and tolerability as a single therapy in sorafenib-resistant patients with HCC in the first half of 2017.

See more Milciclib clinical trials

Foralumab

Tiziana is currently conducting a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston.

See more Foralumab clinical trials

Tiziana Life Sciences is listed on NASDAQ and AIM